|
 Dr. Janet Woodcock, head of the FDA's pharmaceuticals division, said
at a news conference that the project, some 10 years in the making,
is designed to establish consistent quality standards for all drugs,
whether brand name or generic.
The FDA has established an Office of Pharmaceutical Quality that
will be responsible for some 10,000 decisions a year and manage the
process.
Drugs currently being evaluated for approval will remain with their
existing review team at the FDA. New applications will be filed with
the new office beginning immediately, Woodcock said.
Under the new structure, drug companies can expect a more integrated
review and greater communication with the agency, she said.
The FDA will propose a set of quality metrics for drugmakers. After
a public comment period the agency will produce a final rule.
Woodcock was not able to give any time-frame for when that might be.
Between 2013 and 2014, the number of drug recalls fell by 20
percent, and the Class I recalls, the most dangerous to public
health, fell by 30 percent, according to Todd Harris, vice president
of recalls at recall-manager Stericycle Inc.
Still, the absolute numbers remain eye-catching.
The average annual number of recalled units between 2010 and 2012
was 225 million, Harris said. The number between 2013 and 2014 was
roughly 70 million units.
"While we can't say explicitly the cause of the downward trend, what
we do know is that there is a trend of increasing regulatory
scrutiny, which may cause manufacturers to adhere to stricter
quality guidelines," Harris said.
[to top of second column] |
Over the past year the FDA banned numerous generic drugs from India,
citing quality control problems ranging from data manipulation to
sanitation. India supplies roughly 40 percent of generic and
over-the-counter drugs used in the United States.
Brand name drug companies have not immune either. Johnson & Johnson,
for example, has been forced to recall dozens of products over the
past few years, ranging from artificial hips to children's Tylenol.
Up until now, Woodcock said, the FDA has only had a general sense of
the state of manufacturing quality at the country's drugmakers. Now,
she said, the FDA will have quantitative information.
(Reporting by Toni Clarke in Washington; Editing by Lisa Shumaker)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
